Latest Lead News

AVADA Group Limited reported an 11% revenue increase to $101.5 million in H1 FY26, driven by strong growth in Queensland and New South Wales and early gains from its business transformation. Despite a statutory loss, adjusted EBITDA improved, setting the stage for a stronger second half.

Beonic Limited reported a 5.5% revenue increase to $11.2 million and reduced its net loss to $1.44 million for the half-year ending December 2025. The company also repaid a $4.65 million loan and secured a major $7.3 million contract to deploy passenger flow management solutions across seven Moroccan airports.

MCS Services Limited has finalized a revised agreement to sell the core assets of its subsidiary Highways Traffic Pty Ltd to Altus Traffic for $1.16 million, pending shareholder approval. This marks a strategic step in MCS’s ongoing business realignment following the sale of its larger security division.

NOVONIX Limited posted a $92.7 million net loss for 2025 while progressing its synthetic graphite anode materials business and preparing to divest its Battery Technology Solutions segment.

Ovanti Limited announces a strategic leadership change in its US operations to boost its BNPL platform Flote’s commercialisation and prepare for a potential NASDAQ listing via SPAC.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

Bapcor Limited reported a statutory loss of $104.8 million for the first half of FY26 and announced a fully underwritten $200 million equity raising to strengthen its balance sheet and support operational recovery.

Bioxyne Limited has reported a remarkable half-year performance, with revenues soaring 149% to $31.3 million and net profit more than doubling to $7.3 million, driven by strong demand for medicinal cannabis, MDMA, and psilocybin products and expanding international operations.

Bapcor Limited reported a statutory loss of $104.8 million for the first half of FY26, alongside an underlying profit in line with guidance. The company announced a $200 million equity raising to strengthen its balance sheet and fund a strategic turnaround.

Neurizon Therapeutics has commenced dosing in a major Phase 2/3 trial of its lead drug NUZ-001 for ALS, marking a critical step in advancing treatment options for this devastating disease.

Qoria Limited reported a 25% revenue increase to nearly $69 million for H1 FY2026 but also a widening net loss of $24.5 million. The company announced a transformative merger with US-based Aura to create a global digital safety leader.

Aurelia Metals Limited reported a robust half-year result for December 2025, with revenue climbing 27% and net profit after tax rising 26%, driven by production ramp-up at the Federation Mine and progress on the Great Cobar Project.